Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian M McDonald

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
The Journal of Biological Chemistry|May 1, 2020
Enigmatic MELK: The controversy surrounding its complex role in cancerIan M McDonald, Lee M Graves
Journal of Cellular Biochemistry|May 3, 2017
Measuring Kinase Activity-A Global ChallengeMarissa L Cann, Ian M McDonald, Michael P East, et al.
Biochimica Et Biophysica Acta. General Subjects|December 28, 2019
Lyn regulates creatine uptake in an imatinib-resistant CML cell lineDenis O Okumu, Lucas J Aponte-Collazo, Brian J Dewar, et al.
The Journal of Biological Chemistry|January 4, 2020
Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cellsIan M McDonald, Gavin D Grant, Michael P East, et al.
Molecular & Cellular Proteomics : MCP|February 27, 2017
Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) AntiviralsKyle C Arend, Erik M Lenarcic, Heather A Vincent, et al.
ACS Chemical Biology|April 26, 2019
Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related AnaloguesPaul R Graves, Lucas J Aponte-Collazo, Emily M J Fennell, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 10, 2018
Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell GrowthLinas J Krulikas, Ian M McDonald, Benjamin Lee, et al.
ACS Chemical Biology|July 25, 2022
Correction to "Mitochondrial Protease ClpP Is a Target for the Anticancer Compounds ONC201 and Related Analogues"Paul R Graves, Lucas J Aponte-Collazo, Emily M J Fennell, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
The Journal of Biological Chemistry|May 1, 2020
Enigmatic MELK: The controversy surrounding its complex role in cancerIan M McDonald, Lee M Graves
Journal of Cellular Biochemistry|May 3, 2017
Measuring Kinase Activity-A Global ChallengeMarissa L Cann, Ian M McDonald, Michael P East, et al.
Biochimica Et Biophysica Acta. General Subjects|December 28, 2019
Lyn regulates creatine uptake in an imatinib-resistant CML cell lineDenis O Okumu, Lucas J Aponte-Collazo, Brian J Dewar, et al.
The Journal of Biological Chemistry|January 4, 2020
Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cellsIan M McDonald, Gavin D Grant, Michael P East, et al.
Molecular & Cellular Proteomics : MCP|February 27, 2017
Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) AntiviralsKyle C Arend, Erik M Lenarcic, Heather A Vincent, et al.
ACS Chemical Biology|April 26, 2019
Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related AnaloguesPaul R Graves, Lucas J Aponte-Collazo, Emily M J Fennell, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 10, 2018
Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell GrowthLinas J Krulikas, Ian M McDonald, Benjamin Lee, et al.
ACS Chemical Biology|July 25, 2022
Correction to "Mitochondrial Protease ClpP Is a Target for the Anticancer Compounds ONC201 and Related Analogues"Paul R Graves, Lucas J Aponte-Collazo, Emily M J Fennell, et al.
Pageof 1